Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ted W Johnson

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug DesignHengmiao Cheng, Chunze Li, Simon Bailey, et al.
Bioorganic & Medicinal Chemistry Letters|November 2, 2010
Azaindole N-methyl hydroxamic acids as HIV-1 integrase inhibitors-II. The impact of physicochemical properties on ADME and PKSteven P Tanis, Michael B Plewe, Ted W Johnson, et al.
The New England Journal of Medicine|December 25, 2015
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198FAlice T Shaw, Luc Friboulet, Ignaty Leshchiner, et al.
Journal of Medicinal Chemistry|March 31, 2011
Design and synthesis of novel N-hydroxy-dihydronaphthyridinones as potent and orally bioavailable HIV-1 integrase inhibitorsTed W Johnson, Steven P Tanis, Scott L Butler, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2015
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutationsHelen Y Zou, Qiuhua Li, Lars D Engstrom, et al.
Nature Cancer|June 21, 2022
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancerAya Shiba-Ishii, Ted W Johnson, Ibiayi Dagogo-Jack, et al.
Neuro-Oncology|September 26, 2015
CNS Anticancer Drug Discovery and Development Conference White PaperVictor A Levin, Peter J Tonge, James M Gallo, et al.
Cancer Discovery|April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung CancerSatoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2021
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung CancerJessica J Lin, Noura J Choudhury, Satoshi Yoda, et al.
Cancer Cell|July 7, 2015
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical ModelsHelen Y Zou, Luc Friboulet, David P Kodack, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug DesignHengmiao Cheng, Chunze Li, Simon Bailey, et al.
Bioorganic & Medicinal Chemistry Letters|November 2, 2010
Azaindole N-methyl hydroxamic acids as HIV-1 integrase inhibitors-II. The impact of physicochemical properties on ADME and PKSteven P Tanis, Michael B Plewe, Ted W Johnson, et al.
The New England Journal of Medicine|December 25, 2015
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198FAlice T Shaw, Luc Friboulet, Ignaty Leshchiner, et al.
Journal of Medicinal Chemistry|March 31, 2011
Design and synthesis of novel N-hydroxy-dihydronaphthyridinones as potent and orally bioavailable HIV-1 integrase inhibitorsTed W Johnson, Steven P Tanis, Scott L Butler, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2015
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutationsHelen Y Zou, Qiuhua Li, Lars D Engstrom, et al.
Nature Cancer|June 21, 2022
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancerAya Shiba-Ishii, Ted W Johnson, Ibiayi Dagogo-Jack, et al.
Neuro-Oncology|September 26, 2015
CNS Anticancer Drug Discovery and Development Conference White PaperVictor A Levin, Peter J Tonge, James M Gallo, et al.
Cancer Discovery|April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung CancerSatoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2021
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung CancerJessica J Lin, Noura J Choudhury, Satoshi Yoda, et al.
Cancer Cell|July 7, 2015
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical ModelsHelen Y Zou, Luc Friboulet, David P Kodack, et al.
Pageof 3